Shinji Furuta - Publications

Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.

Journal: Diabetes & vascular disease research

Published: December 29, 2020

Quality of Life and Emotional Distress in Peritoneal Dialysis and Hemodialysis Patients.

Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

Published: July 26, 2019

Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.

Journal: European journal of clinical investigation

Published: March 01, 2018

Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.

Journal: Journal of diabetes investigation

Published: December 19, 2017

Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study.

Journal: Drug research

Published: July 25, 2017

The Vasopressin 2 Receptor Antagonist Tolvaptan Improves Nutrition and Inflammatory States in Peritoneal Dialysis Patients with Diabetes Mellitus.

Journal: Advances in peritoneal dialysis. Conference on Peritoneal Dialysis

Published: December 31, 2015

Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis.

Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

Published: November 12, 2015